Elle, MD Biotechnologies, Inc

Elle, MD Biotechnologies, Inc, located in Nova Scotia, Canada, specializes in developing innovative non-hormonal contraceptive solutions, including its flagship product, The Better Ring™, aimed at enhancing women's reproductive health. Founded in 2022, Elle, MD Biotechnologies, Inc operates out of Nova Scotia, Canada. The company focuses on creating effective non-hormonal contraceptive methods. There have been no notable pivots or changes in business operations since its inception.

Elle, MD is a standalone entity without subsidiaries or a parent company. The company was founded by individuals whose details are not available. In 2025, Elle, MD Biotechnologies raised USD 0. 1 million in the latest funding round from Invest Nova Scotia, bringing the total amount raised to USD 0.

1 million through 1 deal. Elle, MD Biotechnologies, Inc develops innovative, non-hormonal contraceptive solutions, notably The Better Ring™, which utilizes a copper-based mechanism to inhibit fertilization while preserving women's menstrual cycles. The company targets women of reproductive age, addressing the demand for safer contraceptive options. Elle, MD aims to expand its product line to include emergency contraception and seeks to establish a strong market presence in North America and Europe, responding to the urgent need for reliable birth control.

Elle, MD generates revenue through direct-to-consumer sales of The Better Ring™, with customers accessing the product via healthcare providers, pharmacies, or directly from the company. The pricing reflects the product's premium positioning in the contraceptive market, catering to health-conscious consumers. The company is also pursuing partnerships with healthcare organizations to expand its reach and enhance product awareness. In October 2025, Elle, MD Biotechnologies plans to leverage USD 0.

1 million raised from Invest Nova Scotia to complete proof-of-concept preclinical safety and efficacy studies, alongside biocompatibility and chemical testing. The company is actively working on developing new products, including emergency contraceptives, and aims to expand its market presence in North America and Europe by 2025.